Detalhe da pesquisa
1.
Active and non-active progression independent of relapse activity within the first 20 years of relapsing multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 2024 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38719433
2.
Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis.
Mult Scler
; 30(2): 261-265, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38166437
3.
Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society.
Mult Scler
; 30(7): 899-924, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38357870
4.
Factors affecting the topography of nitrous oxide-induced neurological complications.
Eur J Neurol
; 31(7): e16291, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38532638
5.
Grey-matter sodium concentration as an individual marker of multiple sclerosis severity.
Mult Scler
; 28(12): 1903-1912, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35723278
6.
Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases.
Ann Neurol
; 87(2): 256-266, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31725931
7.
TNF-α inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosis.
J Neurol Neurosurg Psychiatry
; 2021 Jun 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34103339
8.
Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis.
Mult Scler
; 27(5): 712-718, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32202216
9.
Comparison of rituximab originator (MabThera®) to biosimilar (Truxima®) in patients with multiple sclerosis.
Mult Scler
; 27(4): 585-592, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32180508
10.
Efficacy of rituximab in refractory RRMS.
Mult Scler
; 25(6): 828-836, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29722639
11.
Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
Mult Scler
; 24(6): 811-813, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29359614
12.
Improvement of spasticity following intermittent theta burst stimulation in multiple sclerosis is associated with modulation of resting-state functional connectivity of the primary motor cortices.
Mult Scler
; 23(6): 855-863, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27481208
13.
Cortical Lesions as an Early Hallmark of Multiple Sclerosis: Visualization by 7 T MRI.
Invest Radiol
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38889240
14.
Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis.
Neurol Neuroimmunol Neuroinflamm
; 11(3): e200231, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38626360
15.
Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception.
Neurol Neuroimmunol Neuroinflamm
; 10(5)2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37550074
16.
Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?
Neurol Neuroimmunol Neuroinflamm
; 10(5)2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37604695
17.
Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab.
Neurol Neuroimmunol Neuroinflamm
; 9(1)2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34815322
18.
Pure Relapsing Short Myelitis: Part of the Multiple Sclerosis Spectrum or New Entity?
Neurol Neuroimmunol Neuroinflamm
; 9(4)2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35473885
19.
Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody-Associated Diseases.
Neurol Neuroimmunol Neuroinflamm
; 8(3)2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33722933
20.
Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy.
Mult Scler J Exp Transl Clin
; 7(4): 20552173211062142, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34925877